The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of ...

Shares of at least four other developers were up by mid-single digits to low-double digits at certain points on Tuesday.

Compass Pathways on Tuesday disclosed results from two Phase 3 studies that support a potential approval of its psilocybin treatment for severe depression, but more detailed data are needed to ...

A review of recent research suggests that the testing methods may have led to overly optimistic expectations. A competitive drug has been approved and appears to be making excellent commercial headway ...

Compass Pathways' Phase 3 COMP-360 data met primary endpoints but disappointed versus analyst expectations, triggering a 50% stock drop and highlighting sector skepticism. Key hurdles for Compass ...

Feb 17 (Reuters) - Drug developer Compass Pathways said on Tuesday its psilocybin-based depression therapy reduced the severity of symptoms in a late-stage study, sending its shares up nearly 23%. The ...